Sanofi completes Inhibrx acquisition for $1.7B

Sanofi Completes Inhibrx Acquisition for $1.7B

Sanofi agreed to buy all outstanding Inhibrx shares for $30.00 in cash, valuing the company at about $1.7 billion. The merger closed on May 30, 2024, making Inhibrx an indirect wholly owned Sanofi subsidiary. The deal brings INBRX-101, an optimized recombinant alpha-1 antitrypsin augmentation therapy, into Sanofi's inflammation-focused pipeline.

IntelligenceCompetitive Intelligence▾

Competitive pressure is high. Sanofi and Inhibrx reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.

Key Takeaways

• Sanofi acquired all outstanding Inhibrx shares for $30.00 per share in cash, representing an equity value of approximately $1.7 billion on a fully diluted basis.
• The transaction closed on May 30, 2024, with Inhibrx continuing as the surviving corporation and becoming an indirect, wholly owned Sanofi subsidiary.
• The acquisition includes INBRX-101, an optimized, recombinant alpha-1 antitrypsin (AAT) augmentation therapy, expanding Sanofi's inflammation-focused pipeline.
• The deal represents a strategic entry into rare disease treatment for alpha-1 antitrypsin deficiency, a chronic inflammatory condition requiring augmentation therapy.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for inflammation. Hospital consolidation and provider M&A can shift formulary control and regional contracting — recalibrate forecasts accordingly.

Sanofi Acquires Inflammation Specialist Inhibrx: Deal Structure and Timeline

Sanofi announced the Sanofi Inhibrx acquisition on January 23, 2024, and completed the merger on May 30, 2024. Under the terms of the agreement, Sanofi acquired all outstanding shares of Inhibrx for $30.0 per share in cash, with the deal structured as a merger of an indirect, wholly owned Sanofi subsidiary into Inhibrx. The transaction unfolded over approximately four months from announcement to close, a timeline typical for cash acquisitions in the biopharmaceutical sector.

The equity value of the transaction is approximately $1.7 billion on a fully diluted basis. Following the close, Inhibrx became an indirect, wholly owned subsidiary of Sanofi. The acquisition reflects Sanofi's continued investment in rare disease and inflammation-focused therapeutics, aligning with the company's broader portfolio strategy in specialty care.

IntelligenceStrategic Takeaways▾

Sanofi acquired all outstanding Inhibrx shares for $30.00 per share in cash , representing an equity value of approximately $1.7 billion on a fully diluted basis. The transaction closed on May 30, 2024, with Inhibrx continuing as the surviving corporation and becoming an indirect, wholly owned Sanofi subsidiary. The acquisition includes INBRX-101, an optimized, recombinant alpha-1 antitrypsin (AAT) augmentation thera

What Is INBRX-101 and Why Does It Matter?

The primary asset acquired in the deal is INBRX-101, an optimized, recombinant alpha-1 antitrypsin (AAT) augmentation therapy. This therapeutic addition represents Sanofi's entry into treatment for alpha-1 antitrypsin deficiency, a rare genetic disorder characterized by progressive lung and liver disease. By acquiring Inhibrx Biosciences and its clinical-stage asset, Sanofi gains access to a targeted therapeutic approach in a specialized indication where treatment options remain limited. The acquisition expands Sanofi's inflammation-focused pipeline and provides a platform for potential additional development in augmentation therapies.

IntelligenceEvidence Quality▾

Grounded in 1 peer-reviewed source.

Market Context: Inhibrx Stock and Acquisition Premium

The $30.00-per-share purchase price represented the agreed valuation for Inhibrx shareholders. The Sanofi Inhibrx premium reflected investor confidence in the company's development progress and the strategic value of INBRX-101 to Sanofi's portfolio. For investors tracking Inhibrx stock prior to the acquisition announcement, the deal represented a clear exit event and capital return. The transaction also signals continued M&A activity in the rare disease and inflammation therapeutic space, where specialized biopharmaceutical companies have attracted significant acquisition interest from larger pharmaceutical players.

Frequently Asked Questions

Related profiles

• Sanofi